Browsing tag:

beta-blocker


Carvedilol Phosphate, CAS number 72956-09-3, is known as the blockbuster medication Coreg CR. GlaxoSmithKline holds the patent for Coreg CR until February 7, 2016. Useful for treating patients with hypertension and mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, carvedilol phosphate is available for research and development from LGM Pharma. In the group of[…]

Read More

Nebivolol, CAS# 99200-09-6, is recognized as the brand name anti-hypertensive drug Bystolic, which is marketed by Forest Pharmaceuticals, Inc. This beta-blocker powerhouse has a patent expiration of June 2, 2015, and is projected to become a widely used generic treatment for chronic hypertension. Current dosages of Bystolic, or nebivolol,  2.5, 5, 10, and 20 milligram[…]

Read More

Carvedilol, CAS# 72956-09-3, is known as the brand name Coreg, which is marketed by GlaxoSmithKline. The patent for Coreg will expire on June 7, 2015, making way for a generic market. As a beta-blocker used to treat hypertension and heart failure, carvedilol is also often prescribed to treat and prevent heart attack symptoms. Carvedilol is[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service